1968

Lupin commences business

1972

Lupin Laboratories Pvt. Ltd. is incorporated

1979

First Formulations Plant and R&D Center at Aurangabad is commissioned

1981

Starts the production of Ethambutol

1987

The Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar go on stream

1988

Lupin Human Welfare and Research Foundation (LHWRF) is founded by Desh Bandhu Gupta

1989

Receives US FDA approvals for Ankleshwar and Mandideep plants

1991

Initiates production of Injectable Cephalosporins (API and Finished Product) at Mandideep

1992

Establishes a Fermentation plant at Lupin Chemicals Ltd. Tarapur, Maharashtra

1993

IPO of Lupin Laboratories Ltd. and Lupin Chemicals Ltd.

1997

US FDA approval for three plants – Cefaclor at Mandideep, 7 ACCA at Ankleshwar and Rifampicin at Tarapur

1998

Receives U.K. MCA approval for the Injectable Cephalosporin Finished Product Plant at Mandideep

1999

Receives U.K. MCA approval for the Injectable Cephalosporin API plant at Mandideep

2000

Receives US FDA approval for Injectable Cefotaxime (API and Finished Product) at Mandideep

2001

State-Of-The-Art R&D centre, Lupin Research Park at Pune is commissioned

Commences supply of Cephalosporin Finished Product to its Alliance Partners in the U.S.

Lupin Laboratories Ltd. is amalgamated with Lupin Chemicals Ltd., and retitled as Lupin Ltd.

2002

Exports to Advanced Markets cross INR 1000 Mn

Patent filings cross 100

First five ANDAs filed

New Anti-TB Facility commissioned at Aurangabad

Rablet rated by ORGMarg as the second best launch of FY03

2003

Receives WHO approval for finished dosage facility at Aurangabad

Successfully implements SAP ERP across the company to unify all business functions and processes

Receives U.S. FDA approval for the Oral Cephalosporin Plant at Mandideep

Lupin Pharmaceuticals Inc. U.S., formed for commercialization activities in the U.S.

2004

Commences U.S. Branded Business with the launch of Suprax®

2005

Receives US FDA approval for New Lovastatin Plant at Tarapur

Receives US FDA approval for Goa Finished Dosage facility

Launches its Generics Business in the U.S. with four Products

Implements maiden Employees Stock Option Plan

2006

Receives MHRA (U.K.) and WHO approval for Goa finished dosage facility

Maiden bonus shares issued in the ratio of 1:1

Maiden Issue of Foreign Currency Convertible Bonds (FCCB) aggregating USD 100 Mn

2007

Acquires Kyowa Pharmaceutical Industry Company Ltd., a leading Generics Company in Japan

Acquires Vadodara based Rubamin Laboratories Ltd.

Starts commercial production at the new Finished Dosage Facility at Jammu

2008

Sets up a Biotech Facility at Pune

Expands its product basket in Japan-Kyowa and receives approvals for ten products from the Ministry of Health & Labour Welfare, Japan

Acquires Hormosan Pharma Gmbh in Germany

Acquires majority stake in Generic Health Pty Ltd., Australia

Acquires majority stake in Pharma Dynamics, South Africa

2009

Acquires the U.S. Rights for Antara®

Acquires majority stake in Multicare Pharmaceuticals Philippines INC.

2011

Starts Commercial Production at the New Oral Solid Dosage Facility at Pithampur

Acquires I’Rom Pharmaceuticals in Japan

2012

Enters the Nifty 50 Index

2014

Inks Strategic Joint Venture Agreement with Yoshindo Inc. in Japan to launch biosimilars

Acquires Laboratorios Grin S.A. De C.V., Mexico, Specialty Ophthalmic Company and with this enters The Latin American Market

Acquires Nanomi B.V. to enter the Complex Injectables Space

2015

Center of Excellence for Inhalation Research in Coral Springs, Florida is inaugurated

Acquires the Specialty Product Portfolio of Temmler Pharma GmbH & Co. in Germany

Acquires Medquimica Industria Farmaceutica S.A. in Brazil

Completes the acquisition of Pharma Dynamics in South Africa

2016

Commissions a new plant at Tottori, Japan

Bolsters the U.S. Brands Portfolio with Methergine® Oral Tablets

Acquires Branded Product Portfolio from Shionogi & Co. Ltd. in Japan

Completes acquisition of U.S. based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS)

2017

Acquires Symbiomix Therapeutics, LLC in New Jersey for launch of Solosec®

Forays into the OTC Segment with pan-India launch of Softovac®

Inaugurates a new plant at Sikkim

2018

Commissions Injectables Facility at Nagpur

Files New Drug Application for Etanercept Biosimilar in Japan

Signs deal with Illinois-based AbbVie offering exclusive rights to develop and commercialize Lupin’s MALT1 inhibitors (oncology)

2019

Inks partnership with Boehringer Ingelheim to develop and commercialise novel oncology drug

Launches Orphan Drug NaMuscla for treatment of nondystrophic Myotonia

2020

Receives European Marketing Authorization for Nepexto, Biosimilar Etanercept

Receives International Sustainability Rating System (ISRS) Certification for four sites

2021

India business crosses INR 5,000 Cr.

2022

Acquires Southern Cross Pharma in Australia

Completes the acquisition of brands from Anglo-French Drugs & Industries Limited and its Associates